Vascular disease, hypertension, and prevention.
Lavie
Carl J
CJ
Department of Cardiovascular Diseases and Internal Medicine, Ochsner Clinic Foundation, New Orleans, Louisiana 70121-2483, USA. clavier@ochsner.org
D000959:Antihypertensive Agents / Q000627:therapeutic use; D002097:C-Reactive Protein / Q000187:drug effects / Q000378:metabolism; D008076:Cholesterol, HDL / Q000097:blood / Q000187:drug effects; D008078:Cholesterol, LDL / Q000097:blood / Q000187:drug effects; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000097:blood / Q000517:prevention & control; D003920:Diabetes Mellitus / Q000378:metabolism / Q000517:prevention & control; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006973:Hypertension / Q000097:blood / Q000517:prevention & control*; D009765:Obesity; D014652:Vascular Diseases / Q000097:blood / Q000517:prevention & control*; D020246:Venous Thrombosis / Q000097:blood / Q000517:prevention & control
D000959:Antihypertensive Agents; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D002097:C-Reactive Protein